Identification of genetic markers associated with coronary artery disease in Pakistani Pashtun population: A case-control association study

巴基斯坦普什图族人群冠状动脉疾病相关遗传标记的鉴定:一项病例对照关联研究

阅读:1

Abstract

Genetic makers play a critical role in coronary artery disease (CAD) susceptibility. This study investigates the association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) and endothelial nitric oxide synthase (eNOS)-786 T > C polymorphism with CAD in the Pashtun ethnic population of Khyber Pakhtunkhwa, Pakistan. This case-control study was conducted on 1000 individuals, including 500 CAD patients and 500 healthy controls. Genotyping of ACE I/D and eNOS-786 polymorphisms was performed using polymerase chain reaction and polymerase chain reaction-restriction fragment length polymorphism techniques. The association of polymorphisms with CAD risk was analyzed using logistic regression to determine odds ratios (ORs) with 95% confidence intervals (CIs). The ACE deletion (D) allele was significantly more frequent in CAD patients than in controls (OR = 4.76, 95% CI: 3.21-7.08, P < .001), indicating a strong genetic predisposition. Similarly, individuals with the ACE DD genotype had a markedly higher risk of CAD (OR = 6.42, 95% CI: 3.89-10.59, P < .001) compared to individuals with II genotype. In contrast, no significant association was observed between eNOS-786 polymorphism and CAD risk (OR = 1.08, 95% CI: 0.72-1.61, P = .98). The ACE I/D polymorphism, particularly the DD genotype, is strongly associated with an increased risk of CAD in the Pashtun population, while eNOS-786 polymorphism does not appear to be a significant risk factor. These findings underscore the importance of genetic screening for early risk assessment and developing intervention therapies according to genetic make-up of individuals for more effective disease prevention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。